ALLMedicine™ Osteosarcoma Center
Research & Reviews 4,252 results
https://doi.org/10.1186/s13256-022-03469-6 10.1200/JCO.2002.20.3.776 10.1186/1752-1947-4-70 10.1002/cncr.24121 10.1002/cncr.26037 10.1200/JCO.1992.10.10.1579 10.1093/jnci/djk015 10.1016/S0140-6736(97)02307-6 10.1200/JCO.2000.18.24.4016 10.1200/JCO.1988.6.2.329 10.1016/S1470-2045(16)30214-5 10.1093/annonc/mdg286 10.1200/JCO.1987.5.8.1191 10.1200/JCO.2002.20.2.426 10.1200/JCO.18.02374 10.1093/annonc/mdr151 10.1016/S1470-2045(14)71136-2 10.1056/NEJMra0904569 10.1002/ajh.2830440109 10.3109/08880019309016549 10.1016/j.gore.2019.02.006 10.1111/j.1447-0756.2010.01454.x 10.1186/s13256-017-1241-3 10.1053/j.ackd.2013.07.001 10.1182/blood.V120.21.238.238 10.1016/0002-9343(93)90174-N 10.3324/haematol.11575 10.1111/j.1365-2141.2004.05094.x 10.1007/BF00860751 10.1016/j.emc.2018.04.007 10.3109/10428190903456959
Journal of Medical Case Reports; Luminais SN, Chen XT et. al.
Jun 28th, 2022 - Tumor lysis syndrome is an oncologic emergency that involves multiple metabolic abnormalities and clinical symptoms such as acute renal failure, cardiac arrhythmias, seizures, and multiorgan failure, and may be fatal if not promptly recognized. Tu...
https://doi.org/10.1186/s13018-022-03181-7 10.3390/cells9040976 10.1016/j.jbo.2016.05.003 10.1038/onc.2017.225 10.1073/pnas.1525387114 10.1016/j.molcel.2011.08.018 10.1038/nrg3606 10.1016/j.ymthe.2019.05.011 10.18632/aging.103476 10.18632/aging.102325 10.1002/mgg3.1349 10.1016/j.jaci.2017.08.034 10.1016/j.ymthe.2017.05.018 10.3233/CBM-181527 10.1016/j.cell.2011.09.028 10.1016/j.cell.2011.07.014 10.1136/jmedgenet-2015-103334 10.1002/jcp.27587 10.1158/0008-5472.CAN-19-0799 10.1016/j.prp.2019.152762 10.2147/OTT.S220072 10.1186/s12943-017-0680-1 10.1038/s41388-019-0747-0
Journal of Orthopaedic Surgery and Research; Shuang O, Zhou J et. al.
Jun 28th, 2022 - As a skeletal malignancy, osteosarcoma has high incidence among primary malignant bone tumors. With increasing researches on molecules which mediate cancer progression, molecular mechanism has gradually become the pivot of osteosarcoma research an...
https://doi.org/10.1055/a-1842-7545
Drug Research; Khyavi PA, Valizadeh A et. al.
Jun 28th, 2022 - Recently, various studies have concentrated on the therapeutic potential of thymoquinone (TQ), a natural polyphenol, in various human malignancies, including osteosarcoma. However, the underlying mechanisms in TQ-mediated anti-cancer effects are n...
https://clinicaltrials.gov/ct2/show/NCT01804634
Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...
https://clinicaltrials.gov/ct2/show/NCT02522611
Jun 24th, 2022 - Cancer-induced bone pain (CIBP) is a common clinical problem. While primary osteosarcoma is relatively uncommon, bone metastases frequently cause cancer-related pain with metastatic spread to bone in 60-84% of cases. Resiniferatoxin (RTX) is an ul...
Guidelines 4 results
https://doi.org/10.1016/j.otsr.2018.12.015
Orthopaedics & Traumatology, Surgery & Research : OTSR; Gomez-Brouchet A, Mascard E et. al.
Apr 10th, 2019 - Standardized reports are essential to meeting the bone sarcoma reference center certification requirements of the French National Cancer Institute (INCa). The usual classifications of the Musculoskeletal Tumor Society (MSTS), the American Joint Co...
https://doi.org/10.1093/annonc/mdu153
Annals of Oncology : Official Journal of the European Soc... Wilhelm M, Dirksen U et. al.
Jun 26th, 2014 - Teenagers and young adults (TYA) cancer contributes substantially to morbidity and mortality in a population with much to offer society. TYA place distinct challenges upon cancer care services, many reporting feeling marginalized and their needs n...
https://doi.org/10.1093/annonc/mdn102
Annals of Oncology : Official Journal of the European Soc... Bielack S, Carrle D et. al.
May 9th, 2008 - Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Bielack S,Carrle D,Jost L, ,|diagnosis,epidemiology,pathology,therapy,therapy,diagnosis,epidemiology,pathology,therapy,
https://doi.org/10.1002/pbc.21596
Pediatric Blood & Cancer; Meyer JS, Nadel HR et. al.
May 6th, 2008 - The Children's Oncology Group (COG) is a multi-institutional cooperative group dedicated to childhood cancer research that has helped to increase the survival of children with cancer through clinical trials. These clinical trials include a standar...
Drugs 40 results see all →
Clinicaltrials.gov 250 results
https://clinicaltrials.gov/ct2/show/NCT01804634
Jun 24th, 2022 - Allogeneic hematopoietic stem cell transplantation (HSCT) may be associated with a clinically significant "graft-versus-tumor" (GVT) effect, even against disease that is unresponsive to chemotherapy and radiation therapy. Graft-vs.-tumor (GVT) eff...
https://clinicaltrials.gov/ct2/show/NCT02522611
Jun 24th, 2022 - Cancer-induced bone pain (CIBP) is a common clinical problem. While primary osteosarcoma is relatively uncommon, bone metastases frequently cause cancer-related pain with metastatic spread to bone in 60-84% of cases. Resiniferatoxin (RTX) is an ul...
https://clinicaltrials.gov/ct2/show/NCT02504879
Jun 24th, 2022 - Melorheostosis is a rare osteosclerotic disease resulting in exuberant excessive bone growth with a characteristic radiographic appearance often described as dripping candle wax. As a result of these bony formations, patients report mild-moderate ...
https://clinicaltrials.gov/ct2/show/NCT05235165
Jun 23rd, 2022 - PRIMARY OBJECTIVE: I. To determine if open surgical resection is superior to thoracoscopic resection for thoracic event-free survival (tEFS) in patients with resectable oligometastatic pulmonary osteosarcoma. SECONDARY OBJECTIVES: I. To determine ...
https://clinicaltrials.gov/ct2/show/NCT04870944
Jun 23rd, 2022 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of FACT complex-targeting curaxin CBL0137 (CBL0137) administered via infusion on Day 1 and Day 8 of a 21-day cycle to children with recurren...
News 128 results
https://www.onclive.com/view/fda-accepts-nda-resubmission-for-pedmark-in-prevention-of-platinum-induced-ototoxicity-in-solid-tumors
Apr 28th, 2022 - The FDA has accepted for filing the new drug application (NDA) resubmission for a unique formulation of sodium thiosulfate (Pedmark) for the prevention of platinum-induced ototoxicity in patients between the ages of 1 month and 18 years who have l...
https://www.onclive.com/view/nda-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors
Apr 28th, 2022 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...
https://www.medscape.com/viewarticle/960703
Oct 12th, 2021 - Investigators in China have identified 14 immune-related genes associated with survival in osteosarcoma. When they combined them into a risk score and added one additional factor – metastases at diagnosis – the model was an "excellent" predictor o...
https://www.onclive.com/view/key-advances-in-sarcoma-lead-to-more-personalized-medicine-efforts
Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...
https://www.onclive.com/view/intriguing-research-brings-hope-to-orthopedic-oncology
Oct 6th, 2021 - R. Lor Randall, MD, FACS The orthopedic oncology community has not seen many treatment advances due to the rarity of bone cancers, but emerging research could serve as a turning point for the specialized paradigm, explained R. Lor Randall, MD, FA...
